PARP1 and cancer: Accordingly, a number of PARP inhibitors (PARPi) have been developed, showing clinical effectiveness mainly for cancers (i.e., breast, ovarian, pancreatic, prostate) with deleterious mutations in BRCA genes, or other deficiency in the homologous recombination repair (HRR) pathway (3, 4).